Pneumovax 23 Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of national immunization guidelines, rising incidence of pneumococcal infections in elderly populations, availability of polysaccharide vaccines, growth in preventive healthcare initiatives, increased vaccination awareness.

The growth in the forecast period can be attributed to increasing investments in adult vaccination programs, rising focus on infectious disease prevention, expansion of pharmacy-based immunization services, growing demand for long-term vaccine protection, advancements in vaccine storage and distribution. Major trends in the forecast period include increasing focus on adult and geriatric immunization programs, rising demand for pneumococcal disease prevention, growing adoption of preventive vaccination strategies, expansion of public health immunization campaigns, enhanced cold-chain vaccine management.

The rising incidence of pneumococcal diseases is expected to support the expansion of the pneumovax 23 market in the coming years. Pneumococcal diseases are infections caused by the bacterium *Streptococcus pneumoniae*, commonly referred to as pneumococcus, and can result in a wide range of health conditions, from mild illnesses such as sinusitis and otitis media to severe and potentially life-threatening diseases including pneumonia and meningitis that may require hospitalization. The growing incidence of pneumococcal diseases is linked to factors such as decreased vaccination coverage during the COVID-19 pandemic, increased vulnerability among individuals with chronic health conditions, and the resurgence of respiratory infections following the relaxation of social restrictions. Pneumovax 23 helps prevent pneumococcal infections by providing immunity against 23 strains of *Streptococcus pneumoniae*, thereby lowering the risk of conditions such as pneumonia, meningitis, and bacteremia. For instance, in June 2025, according to the Office for Health Improvement and Disparities, a UK-based public health authority, emergency hospital admissions for pneumonia in England increased by 16% in the financial year ending 2024 compared to the previous year, reaching 430 admissions per 100,000 people and totaling approximately 252,912 cases. Therefore, the increasing global incidence of pneumococcal diseases is driving the growth of the pneumovax 23 market.

The expansion of government-led immunization programs is expected to contribute to the growth of the pneumovax 23 market in the future. Government immunization programs are coordinated efforts by national and local authorities to promote and deliver vaccines to populations, aiming to prevent vaccine-preventable diseases, raise immunization coverage, and improve public health outcomes through routine vaccination schedules, large-scale campaigns, and awareness initiatives. The growth of these programs is driven by efforts to strengthen public health systems, close immunization gaps that emerged during the COVID-19 pandemic, and ensure equitable vaccine access to reduce the spread of infectious diseases. Such initiatives support the uptake of Pneumovax 23 by improving vaccine availability, enhancing public awareness, and increasing vaccination rates against pneumococcal infections. For example, in July 2024, according to Gavi, a Switzerland-based global vaccine alliance, approximately 69 million children received Gavi-supported routine immunizations in 2023, nearing record annual levels, while in 2024, more than 72 million children in lower-income countries were vaccinated with Gavi assistance, reflecting continued expansion. Therefore, the expansion of government immunization initiatives is driving the growth of the pneumovax 23 market.

The accelerating pace of urbanization is anticipated to support the growth of the pneumovax 23 market going forward. Urbanization is driven by factors such as industrial development, improved employment opportunities in cities, greater access to education and healthcare, and the appeal of urban lifestyles that attract people from rural areas in search of better living standards. Urban populations generally benefit from increased exposure to health education and awareness campaigns, which can lead to higher vaccination uptake as individuals become more aware of the importance of preventing pneumococcal diseases. For instance, in April 2023, according to the World Bank Group, a US-based international financial institution, around 56% of the global population, or 4.4 billion people, resided in urban areas, a figure projected to rise to nearly 70% by 2050 as urban populations almost double. In addition, urban land consumption is expanding faster than population growth, adding an estimated 1.2 million square kilometers of new urban areas by 2030. Therefore, the increasing rate of urbanization is contributing to the growth of the pneumovax 23 market.

Major companies operating in the pneumovax 23 market are Merck & Co. Inc. (Merck Sharp & Dohme Corp.)

North America was the largest region in the pneumovax 23 market in 2025. The regions covered in the pneumovax 23 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pneumovax 23 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the pneumovax 23 market by increasing costs of imported vaccine raw materials, sterile vials, cold-chain logistics equipment, and specialized packaging components. Hospitals, clinics, and pharmacies in North America and Europe are most affected due to reliance on global vaccine supply chains, while Asia-Pacific faces procurement and distribution cost pressures. These tariffs are increasing vaccine acquisition costs and impacting public health budgeting. However, they are also supporting domestic vaccine manufacturing, regional fill-finish operations, and strengthened local vaccine supply resilience.

The pneumovax 23 market research report is one of a series of new reports that provides pneumovax 23 market statistics, including pneumovax 23 industry global market size, regional shares, competitors with a pneumovax 23 market share, detailed pneumovax 23 market segments, market trends and opportunities, and any further data you may need to thrive in the pneumovax 23 industry. This pneumovax 23 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pneumovax 23 is a vaccine that provides protection against 23 strains of pneumococcal bacteria responsible for serious conditions such as pneumonia, meningitis, and bloodstream infections. It is mainly administered to older adults and individuals with specific health conditions to help prevent invasive pneumococcal disease. The vaccine works by activating the immune system to identify and combat these targeted bacterial strains, offering long-lasting protection.

The primary formulations of Pneumovax 23 include the pneumococcal polysaccharide vaccine (PPV) and the pneumococcal conjugate vaccine (PCV). Pneumococcal polysaccharide vaccines are developed to protect against multiple pneumococcal strains by using polysaccharides derived from bacterial capsules. Pneumovax 23 is a commonly used pneumococcal polysaccharide vaccine that covers 23 pneumococcal strains. It is indicated for the prevention of pneumococcal disease and is utilized by end users such as hospitals, clinics, ambulatory surgical centers, and pharmacies.

The pneumovax 23 market consists of the sales of pneumovax 23 vaccine (the primary 23-valent pneumococcal polysaccharide vaccine). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.